BioAtla

Founded in 2007 by Jay Short, San Diego-based BioAtla is a clinical-stage biopharmaceutical company developing novel antibody therapeutics and conditionally active biologics for solid tumor cancers. The enterprise utilizes its proprietary platform to engineer antibodies that activate specifically within the tumor microenvironment, aiming to increase drug efficacy while minimizing toxicity to healthy tissue. Operating with approximately 70 employees, the firm secured strategic partnerships with major pharmaceutical entities like Pfizer, including an agreement for over one billion dollars in potential milestone payments. The biotechnology developer entered the public markets via an initial public offering on the Nasdaq exchange under the ticker BCAB in December 2020, raising over 217 million dollars. Several of its lead antibody-drug conjugate candidates, including mecbotamab vedotin and ozuriftamab vedotin, have subsequently received Fast Track designations from the FDA for specific cancer indications.